Cargando…
Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) remains to a common cause of tumor mortality worldwide and represents the most common type of lethal hepatic malignancy. The incidence of HCC is swiftly increasing in western countries and southeast Asia. Despite poor prognosis, traditional treatments for advanced HCC...
Autores principales: | Dai, Xinlun, Wang, Shupeng, Niu, Chunyuan, Ji, Bai, Liu, Yahui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432969/ http://dx.doi.org/10.1177/1533033820947486 |
Ejemplares similares
-
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020) -
Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021) -
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)